Vaccine and prior SARS-CoV-2 infection confer long-lasting protection against omicron BA.5

A new study led by Luís Graça, group leader at the Instituto de Medicina Molecular João Lobo Antunes (iMM, Lisbon) and full professor at the Medical School of the University of Lisbon, and Manuel Carmo Gomes, associate professor with aggregation at the Faculty of Sciences of the University of Lisbon (Ciências ULisboa), both members of the Direção Geral de Saúde (DGS) Technical Committee for Vaccination against COVID-19 (CTVC), and published today in the scientific journal Lancet Infectious Diseases, shows that the protection conferred by hybrid immunity against the SARS-CoV-2 subvariant omicron BA.5, obtained by the infection of vaccinated people, lasts for at least eight months after the first infection.